Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

Xtant Medical Holdings (XTNT) EBIAT (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed EBIAT for 16 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIAT rose 126.04% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.8 million, a 109.96% increase, with the full-year FY2024 number at -$16.4 million, down 2592.27% from a year prior.
  • EBIAT was $1.3 million for Q3 2025 at Xtant Medical Holdings, down from $3.6 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $9.2 million in Q3 2023 to a low of -$5.0 million in Q3 2024.
  • A 5-year average of -$1.3 million and a median of -$2.2 million in 2023 define the central range for EBIAT.
  • Peak YoY movement for EBIAT: crashed 7531.03% in 2022, then soared 492.31% in 2023.
  • Xtant Medical Holdings' EBIAT stood at -$2.3 million in 2021, then grew by 3.24% to -$2.2 million in 2022, then crashed by 94.79% to -$4.3 million in 2023, then increased by 26.45% to -$3.2 million in 2024, then skyrocketed by 141.33% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's EBIAT are $1.3 million (Q3 2025), $3.6 million (Q2 2025), and $58000.0 (Q1 2025).